Skip to main content
. 2024 Mar 25;25(7):3646. doi: 10.3390/ijms25073646

Table 1.

Summary of the clinical characteristics of the study population.

Characteristics MRONJ Patients n = 63
Age (years) (mean ± SD) * 69.33 ± 11.06
Sex
Female 46
Male 17
Duration of treatment (months) (mean ± SD) * 46.42 ± 39.77
Disorder *
Breast cancer 26
Prostate cancer 11
Myeloma multiplex 11
Osteoporosis 7
Lung cancer 2
Melanoma malignum 1
Colon cancer 1
Cervical cancer 1
Chemotherapy *
Yes 38
No 22
Hormone deprivation therapy
Yes 32
No 28
Antiresorptive agent *, **
Alendronate (p.o.) 1
Ibandronate (p.o.) 4
Risedronate (p.o.) 1
Zoledronate (iv./inj.) 29
Denosumab (inj.) 29
MRONJ localization *, ***
Maxilla 19
Mandibula 42
MRONJ stage *, ****
1 1
2 44
3 15

* There were no available clinical data for three patients. ** Four patients had both bisphosphonate and denosumab. *** One patient had both maxillar and mandibular involvement. **** Based on the American Association of Oral and Maxillofacial Surgeons’(AAOMS) Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 update.